The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36255176/
doi: 10.14670/HH-18-534. Online ahead of print. 1 Department of Oncology and Center Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, PR China. 2 Cancer Center, The First Affiliated Hospital...
Conclusions: Parafibromin immunoreactivity as an independent factor was positively associated with an increased overall survival rate of breast cancer patients (p<0.05). These findings suggest that up-regulation of parafibromin in breast cancer patients is closely linked to a favorable prognosis. It is involved in tumorigenesis and...
-
Albert Dekker3yrand how easy to do this in clinical practice
Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36364432/
Advances in the treatment of HR+/HER2- breast cancer phenotype have been made with the introduction of abemaciclib, ribociclib, and palbociclib, inhibitors of cyclin D dependent kinases 4 and 6 (CDK4/6)....
Conclusions: A greenness assessment of the proposed method was performed, and the method was shown to be green. The validated method was successfully applied to pharmaceutical dosage forms of all CDK4/6 inhibitors.
-
Albert Dekker3yrgood luck
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36358886/
Pre-surgical treatments in patients with early breast cancer allows a direct estimation of treatment efficacy, by comparing the tumor and the treatment. Patients who achieve a pathological complete response at...
Conclusions: More recently, other treatment strategies have been approved for patients with high-risk early breast cancer, including the immune checkpoint inhibitor pembrolizumab, the PARP inhibitor olaparib and the CDK 4/6 inhibitor abemaciclib. Novel agents and treatment combinations are currently under investigation as promising...
-
Albert Dekker3yrI have started using Keytruda+/- Xeloda in triple negative and Lynparza in bRCA+
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36358806/
1 Xavier University School of Medicine, #23, Santa Helenastraat, Oranjestad, Aruba. 2 Lankenau Institute for Medical Research Philadelphia, 100 East Lancaster Ave., Wynnewood, PA 19069, USA. 3 Pennsylvania Cancer and...
Conclusions: The impact of CDKI on the anti-tumor immune response represents an area of great promise. CDKI therapy resistance that arises provides the opportunity for specific types of new therapies currently in clinical trials.
-
Albert Dekker3yrWhen patients progress they tend to progress fast
A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies
Source : https://tcr.amegroups.com/article/view/67807/html
Breast cancer is a popular malignant disease worldwide. In particular, hormone receptor-positive (HR+) breast cancer is the most common of the subtypes, and many treatment options are now available, including...
Conclusions: We report here a case of long-term survival in advanced breast cancer of 24 years after surgery, and remark for future treatment strategies that not bound by the conventional treatment policy that emphasizes quality of life without aiming for complete cure.
-
Albert Dekker3yrI am not that old but I have several long-term survivors 15 years plus